Transfer factor: A potential agent for immunotherapy of cancer

Meier, Carolin; LoBuglio, Albert F.

doi:10.1007/bf01556190

Cited by 3 publications

(2 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…in other reports, the administration of dlE directly to the tumor was found to reduce tumor size and increase cd2 + , cd4 + , cd8 + and nK cell counts in rats with glioblastoma multiforme (29). dlE as an adjuvant of chemotherapy has been associated with tumor regression and temporary stabilization in several types of cancer (30), such as breast cancer, nasopharyngeal carcinoma (31), metastatic renal carcinoma (32), prostate cancer (33) and others (34).…”

Section: Clinical and Immunological Assessment In Breast Cancer Patiementioning

confidence: 99%

Clinical and immunological assessment in breast cancer patients receiving anticancer therapy and bovine dialyzable leukocyte extract as an adjuvant

Lara¹,

Ixtepan-Turrent²,

Garza-Treviño³

et al. 2010

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Dialyzable leukocyte extract (DLE) is one of the immunological agents used as an adjuvant in cancer therapy; it has been associated with improved quality of life during cancer chemotherapy. Based on these previous findings and on the observed clinical benefits attributed to DLE in other types of cancer, we investigated its clinical and immunological effects as a therapy adjuvant on breast cancer patients who received only chemotherapy, as compared to patients administered bovine DLE (bDLE) as an adjuvant. This study included 43 breast cancer patients who were about to begin chemotherapy. This group was divided as follows: 25 received chemotherapy and bDLE as an adjuvant therapy, and 18 received only chemotherapy without the adjuvant. All patient clinical and immunological responses were monitored. Among patients in the group that received bDLE as adjuvant, 60% showed a complete response, 32% showed a partial response and 8% did not respond. By contrast, in the group without the adjuvant, 39% showed a complete response, 50% displayed a partial response and 11% were non-responders. In addition, bDLE treatment in combination with chemotherapy resulted in the enhancement of the Karnofsky performance scale during chemotherapy. Even though patients underwent several cycles of chemotherapy without bDLE, the lymphocyte population dropped to below the reference value. On the other hand, in patients with bDLE as adjuvant, the CD4(+) and CD8(+) lymphocytes and the B lymphocytes were maintained within the median range of the reference value. The number of natural killer cells also increased after chemotherapy treatment with bDLE as an adjuvant. In conclusion, bDLE treatment contributes to significant immunological recovery in patients that have undergone heavy chemotherapy, increasing the clinical response and quality of life during chemotherapy.

show abstract

Section: Clinical and Immunological Assessment In Breast Cancer Patiementioning

confidence: 99%

Clinical and immunological assessment in breast cancer patients receiving anticancer therapy and bovine dialyzable leukocyte extract as an adjuvant

Lara¹,

Ixtepan-Turrent²,

Garza-Treviño³

et al. 2010

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…Subjects with metastatic breast cancer without DLE had persistent thyroid lesions and new lesion around aorta following 2 years of chemotherapy in contrast to group with retroperitoneal retrohepatic metastases with partial regression after 4 months of DLE treatment and 5 chemotherapy cycles [26]. TF as chemotherapy adjuvant associated with tumor regression and temporary cancer stabilization or reduced demand for other treatment modalities and have meaning as adjuvant therapy in certain malignancies [27].…”

Section: Results -Immunologic and Clinical Responsementioning

confidence: 95%

Untitled

2019

Int J Immunol Immunother

View full text Add to dashboard Cite

Immune Modulating Peptides (IMP) discussed in literature as a universal immunocorrectors with wide areas of usage which balance the immune system without causing global immune suppression or overreaction. The present article aim is to review the effect and drawbacks of IMPs in form of Dialyzable leukocyte Extracts (DLE) or Transfer Factors (TF) during and following chemotherapy, radiotherapy, drugs interactions, cancer response and clinical outcomes in different cases of cancers such as metastatic breast cancer, glioma, prostate cancer, osteosarcoma and others. The considered cases of immune overreaction and IMP's impact include autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and allergic reactions. The most difficult therapeutic decision is to choose the right treatment for patients with cancer and autoimmune diseases as they both attempt to supervise and control the immune system, managing immune cells in opposite sides. As patients with autoimmune disease experience difficulty to stay in such treatment when immune cells stimulated in order to identify and destroy cancer cells the IMP as immunocorrectors become one of the main and only healthy choices. The universal mechanism of IMPs action and the absence of contraindications extend the indications for their use in pediatric practice. This includes the complex treatment of respiratory viral infections, the possibility of using in frequently ill children with clinical signs of immune dysfunction and acute intestinal infections. According to the reports on safety, absence of adverse and side effects along with positive outcome for patients the IMPs considered as valuable immunocorrector.

show abstract

Transfer Factor

Kirkpatrick

Burger

1980

CRC Critical Reviews in Clinical Laboratory Sciences

View full text Add to dashboard Cite

The understanding of passive transfer of cell mediated-immune responses with transfer factor and other cell free materials has progressed to the point that investigators are seeking the chemical identity of the molecule(s) that are responsible for these effects and are working on their mechanisms of action. In addition, clinical trials are underway that should clarify the potential for use of transfer factor in treatment of infections, neoplastic and autoimmune diseases. This chapter will critically review the past and current data concerning the components of transfer factor and their effects on immunologic and inflammatory reactions. Some of the recently developed animal models will be described and evaluated, and the clinical studies that have provided conclusive data regarding efficacy will be reviewed.

show abstract

Transfer factor: A potential agent for immunotherapy of cancer

Cited by 3 publications

References 55 publications

Clinical and immunological assessment in breast cancer patients receiving anticancer therapy and bovine dialyzable leukocyte extract as an adjuvant

Clinical and immunological assessment in breast cancer patients receiving anticancer therapy and bovine dialyzable leukocyte extract as an adjuvant

Untitled

Transfer Factor

Contact Info

Product

Resources

About